Below we list the 39 abstracts presented at the Human Amyloid Imaging Conference held 9 April 2010 in Toronto, Canada. All are published in the Alzforum Papers of the Week database. The accompanying news series covers some of these studies, but far from all; hence, this document offers the curious reader a wealth of new data to peruse. The Alzforum editors are grateful to co-organizer Keith Johnson for obtaining permission to publish the abstracts; we also thank all the authors for their generosity in sharing their latest data with the worldwide Alzheimer research community.—Gabrielle Strobel.

Human Amyloid Imaging 2010 Meeting Abstracts

Lowe VJ, Parisi JE, Jack Jr CR, Kantarci K, Senjem ML, Wiste HJ, Weigand SD, Kemp BJ, Petersen RC. Comparison of PiB distribution on PET with beta-amyloid deposits at autopsy Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Fleisher AS, Schneider JA, Beach TG, Bedell BJ, Zehntner SP, Clark CM, Krautkramer MP, Pontecorvo MJ, Joshi A, Skovronsky DM. Update on florbetapir F 18 (18F-AV-45) PET clinical studies. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Mintun MA, Vlassenko AG, Sheline YI, Morris JC. Prevalence and incidence of beta-amyloid accumulation from cross-sectional and longitudinal [11C] PIB PET imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Mormino EC, Hayenga AO, Yen IV, Rabinovici GD, Baker SL, Jagust WJ. Not quite PIB-positive, not quite PIB-negative: low levels of beta-amyloid deposition in elderly, normal control subjects may precede AD-like changes. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Cohen AD, Price JC, Klunk WE, Weissfeld LA, Redfield AS, Berginc M, Rosario BL, Nebes RD, Mathis CA. Comparison of approaches for establishing cut-offs for [C-11] Pittsburgh Compound B. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Sabri O, Gertz H-J, Dresel S, Heuser I, Bartenstein P, Bürger K, Hiemeyer F, Lehr S, Wittemer-Rump S, Barthel H. Multicenter phase 2 trial to test florbetaben for b-amyloid (Ab) brain PET in Alzheimer’s disease (AD). Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Brooks DJ. Primary outcome analysis of the multicentre phase II trial of 18F-flutemetamol, a Pittsburgh Compound B derivative for in vivo beta amyloid imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Sperling RA, Johnson K, Doraiswamy PM, Reiman EM, Sabbagh MN, Sadowsky CH, Carpenter A, Clark CM, Flitter M, Pontecorvo MJ. Amyloid deposition detected with 18F-AV-45 is related to decreased memory performance in clinically normal older individuals. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Rowe CC, Chetelat G, Pike K, Psych D, Jones G, Ellis K, Li Q-X, Martins R, Ames D, Villemagne VL. A comparison of imaging, cognitive and blood biomarkers for prediction of cognitive decline. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Drzezga A, Becker JA, Sreenivasan A, Talukdar T, Van Dijk K, Sullivan C, Schultz AP, Sepulcre J, Buckner RL, Sperling RA. Relation between hypometabolism, impaired functional connectivity and β-amyloid load in pre-dementia stages of Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Becker JA, Carmasin J, Maye J, Rentz DR, Buckner RL, Sperling RA, Johnson KA. Amyloid deposition and FDG metabolism in relation to age in APOE4 carriers. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Ishii K, Sakata M, Oda K, Ishiwata K, Senda M, Ito K, Kuwano R, Iwatsubo T. The status and the first preliminary results of amyloid imaging in the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) study. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Jack Jr CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Bernstein MA, Gunter JL, Petersen RC, Aisen P, Knopman DS. Brain Aβ amyloid measures and MRI are complimentary predictors of progression from MCI to AD. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Nordberg A, Schöll M, Kadir A, Andreasen N, Almkvist O. PET imaging of fibrillar amyloid in brain more sensitive diagnostic marker than CSF Aβ42? Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Morris JC, Roe CM, Grant EA, Holtzman DM, Fagan AM, Mintun MA. PIB Imaging and CSF biomarkers predict cognitive impairment and dementia of the Alzheimer type (DAT). Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Brück A, Locascio JJ, Gomperts SN, Rentz DM, Becker JA, Memole L, Carmasin J, Maye J, Growdon J, Johnson KA. Patterns of amyloid deposition distinguish non-demented Parkinson’s disease from normal aging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Carmasin JS, Maye JE, Marshall GA, Becker JA, Sperling RA, Rentz DM, Johnson KA. Overestimation of memory performance in normal elderly subjects is associated with amyloid burden in the temporal lobeOverestimation of memory performance in normal elderly subjects is associated with amyloid burden in the temporal lobe. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Carpenter AP, Pontecorvo MJ, Sadowsky C, Hassman HA, Edell S, Clark CM, Hefti F, Joshi A, Burns J, Skovronsky DM. Pharmacokinetics and pharmacodynamics of 18F-AV-45 (florbetapir F 18) PET imaging in Alzheimer’s disease (AD) and healthy control subjects: results of a phase II trial: 18F-AV-45-A03. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Chau WF, Peterson S, Farrar G, Eko-Ebongue S, Barnes C. Evaluation of metabolites of [18F]flutemetamol, an amyloid imaging agent in human and rat in vitro and rat in vivo models. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Chertkow H, Nikelski J, Leger G, Litwin L, Whitehead V, Evans A. Using FDG PET and PIB (Pittsburgh B) PET imaging to distinguish atypical Alzheimer’s disease and fronto-temporal dementia cases. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Edison P, Hinz R, Ramlackhansingh A, Thomas J, Turkheimer FE, Brooks DJ. Can we use pons as a reference region for the analysis of [11C]PIB PET? Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Elmaleh DR, Shoup TM, Johnson K, Selkoe D, Fischman AJ. Evaluation of inositol and benzothiazole derivatives for amyloid-β peptide inhibition and amyloid imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Gomperts SN, Brück A, Locascio JJ, Rentz DM, Becker JA, Memole L, Carmasin J, Sperling RA, Growdon J, Johnson KA. Regional burden of Aβ-amyloid relates to cognitive function in Parkinson’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Hatashita S, Yamasaki H. Progression of MCI associated with amyloid deposition using PIB PET imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Ichise M, Becker G, Barthel H, Patt M, Luthardt J, Gertz H-J, Schultze-Mosgau M, Rohde B, Reininger C, Sabri O. Kinetic modeling of florbetaben PET data to quantify β-amyloid binding in the human brain. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Ikonomovic MD, Abrahamson EE, Mathis CA, Price JC, Srinivasan S, Debnath ML, Hamilton RL, DeKosky ST, Klunk WE. Histological comparison of neocortical β-amyloid plaque labeling using fluorescent derivatives of flutemetamol (3’-F-PiB) and PiB. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Klunk WE, Snitz BE, Cohen AD, Price JC, Mathis CA, DeKosky ST, Lopez OL, Saxton JA. Comparison of longitudinal changes in amyloid deposition and cerebral metabolism in early-onset familial AD. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Langbaum JBS, Chen K, Liu X, Fleisher AS, Reeder S, Bandy D, Alexander GE, Caselli RJ, Reiman EM. Association between pulse pressure and fibrillar amyloidbeta burden in cognitively normal, late middle-aged people at three levels of genetic risk for Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Larvie M, Van Leemput K, Becker JA, Maye JE, Carmasin JS, Sperling RA, Fischl B, Johnson KA. Hippocampal substructural volume in relation to amyloid deposition. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Maye JE, Carmasin JS, Becker JA, Rentz DM, Sperling RA, Johnson KA. Maternal history of dementia is associated with amyloid deposition in clinically normal older individuals. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Park DC, Rodrigue KM, Kennedy KM, Rieck JR, Hebrank AC, Devous MD. Amyloid burden in normal aging: The Dallas Lifespan Brain Study. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Rabinovici GD, Alkalay A, Marchant NL, DeCarli C, Mungas DM, Chui HC, Reed BR, Jagust WJ. Contribution of amyloid and cerebrovascular disease to cognitive impairment in individuals with high vascular risk. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Ramlackhansingh AF, Knight WD, Okello A, Ryan N, Turkheimer F, De Llano SRM, Edison P, Douglas J, Fox NC, Brooks DJ. Amyloid imaging in presenilin 1 mutation carriers with 11C-PiB PET. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Rentz DM, Becker JA, Frey MT, Carmasin J, Maye J, Olson L, Johnson KA, Sperling RA. A challenging test of name retrieval may be sensitive to early amyloid deposition in normals. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Rinne JO, Koivunen J, Scheinin N, Aalto S, Vahlberg T, Någren K, Parkkola R, Viitanen M. PET imaging of amyloid deposition in patients with mild cognitive impairment: A two year follow-up study. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Sojkova J, Zhou Y, Kraut M, Resnick S, Wong DF. Effects of acquisition time in [11C]PIB PET dynamic studies of non-demented older adults. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Thambisetty M, Tripaldi R, Riddoch-Contreras J, An Y, Campbell J, Sojkova J, Kinsey A, Hye A, Guentert A, Resnick S. Proteome-based identification of plasma biomarkers for brain amyloid burden. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy MG, Ding YS, Gelernter J, Carson RE. Amyloid-β burden and neuropsychological test performance in cognitively normal first-degree relatives at varying genetic risk for Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

Vandenberghe R, Thurfjell L, Van Laere K, Buckley CJ, Owenius R, Brooks DJ. Comparison between cerebellum and pons as reference regions for quantification of the amyloid imaging agents [18F]flutemetamol and [11C]PIB. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9. Abstract

This concludes a six-part series of the HAI Amyloid Imaging Conference. View a PDF of Part 6. See also Part 1, Part 2, Part 3, Part 4, Part 5. View PDF of the entire series.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. Toronto: Human Amyloid Imaging Conference Showcases a Maturing Field
  2. Toronto: Ah, The Devil in the Details
  3. Toronto: Last Gift to Science—Hospice Patients Validate Amyloid Ligand
  4. Toronto: Sister 18F Ligands Jostle for Primacy
  5. Geneva: The AstraZeneca Ligand—The Fairest of Them All?

Paper Citations

  1. . Comparison of PiB distribution on PET with beta-amyloid deposits at autopsy. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  2. . Update on florbetapir F 18 (18F-AV-45) PET clinical studies. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  3. . Prevalence and incidence of beta-amyloid accumulation from cross-sectional and longitudinal [11C] PIB PET imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  4. . Not quite PIB-positive, not quite PIB-negative: low levels of beta-amyloid deposition in elderly, normal control subjects may precede AD-like changes. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  5. . Comparison of approaches for establishing cut-offs for [C-11] Pittsburgh Compound B. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  6. . Multicenter phase 2 trial to test florbetaben for b-amyloid (Ab) brain PET in Alzheimer’s disease (AD). Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  7. . Primary outcome analysis of the multicentre phase II trial of 18F-flutemetamol, a Pittsburgh Compound B derivative for in vivo beta amyloid imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  8. . Amyloid deposition detected with 18F-AV-45 is related to decreased memory performance in clinically normal older individuals. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  9. . A comparison of imaging, cognitive and blood biomarkers for prediction of cognitive decline. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  10. . Relation between hypometabolism, impaired functional connectivity and ß-amyloid load in pre-dementia stages of Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  11. . Amyloid deposition and FDG metabolism in relation to age in APOE4 carriers. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  12. . The status and the first preliminary results of amyloid imaging in the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) study. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  13. . Brain Aβ amyloid measures and MRI are complimentary predictors of progression from MCI to AD. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  14. . PET imaging of fibrillar amyloid in brain more sensitive diagnostic marker than CSF Aß42?. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  15. . PIB Imaging and CSF biomarkers predict cognitive impairment and dementia of the Alzheimer type (DAT). Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  16. . Patterns of amyloid deposition distinguish non-demented Parkinson’s disease from normal aging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  17. . Overestimation of memory performance in normal elderly subjects is associated with amyloid burden in the temporal lobeOverestimation of memory performance in normal elderly subjects is associated with amyloid burden in the temporal lobe. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  18. . Pharmacokinetics and pharmacodynamics of 18F-AV-45 (florbetapir F 18) PET imaging in Alzheimer’s disease (AD) and healthy control subjects: results of a phase II trial: 18F-AV-45-A03. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  19. . Evaluation of metabolites of [18F]flutemetamol, an amyloid imaging agent in human and rat in vitro and rat in vivo models. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  20. . Using FDG PET and PIB (Pittsburgh B) PET imaging to distinguish atypical Alzheimer’s disease and fronto-temporal dementia cases. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  21. . Can we use pons as a reference region for the analysis of [11C]PIB PET?. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  22. . Evaluation of inositol and benzothiazole derivatives for amyloid-β peptide inhibition and amyloid imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  23. . Regional burden of Aβ-amyloid relates to cognitive function in Parkinson’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  24. . Progression of MCI associated with amyloid deposition using PIB PET imaging. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  25. . Kinetic modeling of florbetaben PET data to quantify β-amyloid binding in the human brain. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  26. . Histological comparison of neocortical β-amyloid plaque labeling using fluorescent derivatives of flutemetamol (3’-F-PiB) and PiB. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  27. . Comparison of longitudinal changes in amyloid deposition and cerebral metabolism in early-onset familial AD. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  28. . Association between pulse pressure and fibrillar amyloidbeta burden in cognitively normal, late middle-aged people at three levels of genetic risk for Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  29. . Hippocampal substructural volume in relation to amyloid deposition. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  30. . Maternal history of dementia is associated with amyloid deposition in clinically normal older individuals. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  31. . Amyloid burden in normal aging: The Dallas Lifespan Brain Study. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  32. . Contribution of amyloid and cerebrovascular disease to cognitive impairment in individuals with high vascular risk. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  33. . Amyloid imaging in presenilin 1 mutation carriers with 11C-PiB PET. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  34. . A challenging test of name retrieval may be sensitive to early amyloid deposition in normals. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  35. . PET imaging of amyloid deposition in patients with mild cognitive impairment: A two year follow-up study. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  36. . Effects of acquisition time in [11C]PIB PET dynamic studies of non-demented older adults. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  37. . Proteome-based identification of plasma biomarkers for brain amyloid burden. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  38. . Amyloid-ß burden and neuropsychological test performance in cognitively normal first-degree relatives at varying genetic risk for Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;
  39. . Comparison between cerebellum and pons as reference regions for quantification of the amyloid imaging agents [18F]flutemetamol and [11C]PIB. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;

Other Citations

  1. PDF of Part 6

Further Reading

News

  1. PIB-PET Biomarker Study Confirms Bapineuzumab Lowers Amyloid
  2. HAI Seattle: Does Brain Amyloid Correlate With Sagging Metabolism?
  3. Paper Alert: PIB-PET, Brain Biopsies Match Well for Detecting Aβ
  4. Phase 2 Trial of Amyloid Tracer for AD Is Launched
  5. Multi-Paper Alert: More Data That Brain Amyloid Is Bad for You
  6. St. Louis: Imaging Preclinical AD—Can You See it Coming in the Brain?
  7. BOLD New Look—Aβ Linked to Default Network Dysfunction
  8. Imaging Studies Support Cognitive Reserve Theory
  9. HAI Seattle: Aβ May Disrupt Brain Function in Normal Seniors
  10. HAI Seattle: Not Just Amyloid, Not Just PIB
  11. HAI Seattle: Biomarkers Closing in on AD Pathological Sequence?
  12. Cortical Hubs Found Capped With Amyloid